In a cohort of male veterans, osteoporosis was more common in those with thyroid cancer, according to the results of a study published in The Oncologist. Fractures, however, were not.
Naveed Saleh, MD, MS
The 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, which took place May 31–June 4 in Chicago, drew more than 32,000 oncology specialists from around the world.
The US Food and Drug Administration recently approved a new indication for olaparib for maintenance treatment in adult patients with germline or somatic BRCA-mutated advanced epithelial ovarian cancer.
A new trial investigated the efficacy of XELOX vs GEMOX as first-line therapy for advanced biliary tract cancers.
Findings on the efficacy of the RET inhibitor BLU-667 in RET-altered medullary thyroid cancer and papillary thyroid cancer patients was presented at ASCO 2019.
Despite better detection, the incidence of pediatric thyroid cancer increased by 9.5% per year from 2006 to 2013 compared with 1.1% per year from 1973 to 2006.
Study authors evaluated clinically relevant differences in nonwhite vs white pediatric patients with melanoma and atypical melanocytic neoplasms.
The American Cancer Society's Cancer Facts & Figures 2019 report summarized the rate of melanoma over the past 30 years, mortality, and incidence based on sex and ethnicity.
In this installment of Oncology Drug Updates, updates to FDA approvals for pembrolizumab in the treatment of lung cancer and RCC are highlighted.
Vitamin D deficiency may be a negative prognostic indicator for papillary thyroid cancer, according to the results of a recent retrospective study.